• Based on an off patent drug previously approved for a different indication

​

• Undergoing formulation development to enhance performance and reduce production costs

 

• Further formulation development underway to reduce pill burden and improve patient compliance, thus improving the patient experience

​

• Both will provide substantial Intellectual Property opportunities through novel formulation development

​

​